Evidence map›Paper›PMID 40636418›Full record

ReviewiLIVER2022

A

Shan Tang, Li Bai, Wei Zhang, Wenyan Song, Hui Liu, Lei Li, Chen Liang, Zhongping Duan, Sujun Zheng

Erratum issuedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in iLIVER, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Shan TangThe First Unit, Department of Hepatology, Beijing YouAn Hospital, Capital Medical University, Beijing, China.
Li BaiThe Fourth Unit, Department of Hepatology, Beijing YouAn Hospital, Capital Medical University, Beijing, China.
Wei ZhangThe First Unit, Department of Hepatology, Beijing YouAn Hospital, Capital Medical University, Beijing, China.
Wenyan SongDepartment of Radiology, Beijing YouAn Hospital, Capital Medical University, Beijing, China.
Hui LiuDepartment of Pathology, Beijing YouAn Hospital, Capital Medical University, Beijing, China.
Lei LiDepartment of Digestive Center, Beijing YouAn Hospital, Capital Medical University, Beijing, China.
Chen LiangThe First Unit, Department of Hepatology, Beijing YouAn Hospital, Capital Medical University, Beijing, China.
Zhongping DuanThe Fourth Unit, Department of Hepatology, Beijing YouAn Hospital, Capital Medical University, Beijing, China.
Sujun ZhengThe First Unit, Department of Hepatology, Beijing YouAn Hospital, Capital Medical University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Idiopathic portal hypertension (IPH) is defined as the presence of portal hypertension in the absence of a common cause. IPH can have several etiologies, one of which is a genetic disorder. Some genetic mutations, such as KCNN3 and DGUOK, were shown to be related to IPH pathogenesis. This is the first case report of a 22-year-old man who was diagnosed with IPH with a novel heterozygous mutation in the histidine-rich glycoprotein gene (c.545G > C, p.R182T). Using bioinformatics analysis and the protein quantification method, we showed that this novel mutation has a pathogenetic role in IPH. Our study broadens the mutation spectrum of the histidine-rich glycoprotein gene and provides new ideas for IPH etiology.

Indexed as

Case reportHeterozygous mutationHRG geneIPH

Identifiers

PMID40636418
PMCPMC12212594

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.